Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver(Dana-Farber Cancer Institute), Judy E. Garber, Paula D. Ryan(Massachusetts General Hospital), Andrea L. Richardson(Johns Hopkins University), Zoltán Szállási(Boston Children's Hospital), Dennis C. Sgroi(Harvard University), Diana Calogrias(Dana-Farber Cancer Institute), Nadine Tung(Beth Israel Deaconess Medical Center), Leif W. Ellisen(Harvard University), Shridar Ganesan(Rutgers Cancer Institute), Rebecca Gelman(Dana-Farber Cancer Institute), Alexander Miron(Harvard University), Eric P. Winer(Dana-Farber Cancer Institute), Arcangela De Nicolo(Harvard University), Ayodele Buraimoh(Dana-Farber Cancer Institute), Qiyuan Li(Dana-Farber Cancer Institute), Christian Colin(Dana-Farber Cancer Institute), N. Juul(Dana-Farber Cancer Institute), Aquila Fatima(Dana-Farber Cancer Institute), Aron C. Eklund(Dana-Farber Cancer Institute), Chee-Onn Leong(Dana-Farber Cancer Institute), Zhigang C. Wang(Dana-Farber Cancer Institute)
Cited by 983
Related Papers
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
|Cell|2004|3.8k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k